EP
KURA icon

Eversept Partners’s Kura Oncology KURA Stock Holding History

Eversept Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-263,628
Closed -$2.33M – 112
2025
Q3 		$2.33M Buy
+263,628
New +$1.88M 0.16% 64
2024
Q4 		– Sell
-192,398
Closed -$3.76M – 74
2024
Q3 		$3.76M Buy
192,398
+120,081
+166% +$2.43M 0.26% 45
2024
Q2 		$1.49M Buy
+72,317
New +$1.49M 0.1% 67
2023
Q3 		– Sell
-450,622
Closed -$4.77M – 75
2023
Q2 		$4.77M Buy
+450,622
New +$5.33M 0.4% 43

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Eversept Partners's KURA Position: Q4 2025 in Review

Eversept Partners sold out of Kura Oncology (KURA) in Q4 2025, closing a stake of 263,628 shares — an estimated $2.33M sold.

Eversept Partners first reported a position in KURA in Q2 2023 and held it in 4 quarters. The position peaked at $4.77M in Q2 2023. 215 funds tracked by Wall St. Rank hold KURA as of Q4 2025.

  • Eversept Partners reported no remaining Kura Oncology position as of Q4 2025 after selling out during the quarter.
  • Eversept Partners sold 263,628 Kura Oncology shares in Q4 2025, an estimated $2.33M.
  • Eversept Partners first reported a position in Kura Oncology in Q2 2023 and held it in 4 quarters.
  • Eversept Partners's Kura Oncology position peaked at $4.77M in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2025.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.